Key facts
- This page summarizes Arpa Garay's Form 4 filing for Moderna, Inc. (MRNA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Dec 2023, 16:21.
Arpa Garay - 05 Dec 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- MRNA
- Reported as of
- 05 Dec 2023
- Net transaction value
- -$44,182
- SEC form
- 4
- Accepted by SEC
- 07 Dec 2023, 16:21:21 UTC
- Prior SEC filing
- 07 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Dillon, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Arpa Garay filed Form 4 for Moderna, Inc. (MRNA) on 07 Dec 2023.
Change
- Previous filing in this sequence was filed on 07 Sep 2023.
- Current net transaction value: -$44,182.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,141
- Change %
- +37%
- Price
- Shares after
- 4,254
- Date
- 05 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $44,182
- Shares
- -564
- Change %
- -13%
- Price
- $78.34
- Shares after
- 3,690
- Date
- 06 Dec 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,141
- Change %
- -9.1%
- Price
- $0.000000
- Shares after
- 11,405
- Date
- 05 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,141
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Footnote F3
25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.